Request for Proposal
Status: RFP is Closed

Technology Platform to Discover Novel Synthetic Lethal Factors

Request Number
Due Date
Mar 31
Program Manager


Joint research: Technology platform holder

Licensing: Holder of novel synthetic lethal factors


Joint research: Expecting, but not limited to, 1–3 years


To be discussed based on proposals

How to  Apply
Click on "Respond", complete the form to the extent possible, and submit along with other attachment files available. After creating your account for NineSights, your draft will be automatically saved and you can resume later from "Control Center". Please note you do not submit confidential information at this process.
This request for proposals in PDF format is available here.

If you have any questions or request, please feel free to contact us at:

RFP was closed on
May 2019

RFP Title


Technology Platform to Discover Novel Synthetic Lethal Factors
RFP Description

NineSigma, representing Sumitomo Dainippon Pharma Co., Ltd. ( (“Client”), seeks a technology platform to discover synthetic lethal factors that can serve as the target for drug discovery.

The Client has advantages in cancer research. Through cooperation with the proposer, they aim at discovering a novel synthetic lethal factor(s) using proposer’s technology platform and finally creating innovative next-generation molecularly targeted anti-cancer drugs.

In addition to proposals on technology platform, this RFP also welcomes those on novel synthetic lethal factors discovered using the technology platform.

Key Success Criteria

Proposal requirements

The Client expects a proposal that meets one or both of the following items: (1) technology platform and (2) novel synthetic lethal factors.

(1) Technology platform

 Requirements for technology platform are as follows:

  • The following criteria No. 1 and 2, and preferably No. 3 must be met:
  1. Able to modify target genes accurately and comprehensively
    • e.g., Gene editing technology
  2. Able to evaluate the synthetic lethal phenotype effectively
    • e.g., Screening using siRNA
  3. Able to identify synthetic lethal genes from big data analysis
    • e.g., Analysis technique using AI (artificial intelligence) capable of processing/analyzing massive amounts of data including the existing information on genetic mutations and experimental data
  • The proposed technology has superiority over the existing platform technologies
  • The proposed technology is preferably applicable to evaluation/analysis of various combinations of genes and drugs, and multiple drugs, in addition to that of two synthetic lethal genes

 (2) Novel synthetic lethal factor

      A proposal on novel synthetic lethal factors is also welcome.

  • Factors must be discovered using proposer’s technology platform* or evaluation system.
    * In this case, it does not necessarily have to satisfy the requirements for technology platform listed in (1).
Items to be Submitted

Anticipated Project Process

After the preliminary screening of documents, the Client will ask additional questions to promising proposals and conduct direct discussions to select candidates for the final selection. During the selection process, the Client may execute NDA with selected respondents, seek further information disclosure, and discuss specific development targets or potential opportunities. Specifics of any collaboration will be determined through consultation with the concerned parties.

Notes on Response

Proposal shall have clear points and should not include confidential information. Supplemental files may be submitted in addition to the proposal.

Response evaluation

The client will evaluate all responses with the following criteria.

  • Overall scientific and technical merit
  • Approach to proof of concept or performance
  • Economic potential of concept
  • Realism of the proposed plan (action items, timeline, roles, deliverables, cost estimation)
  • Potential for proprietary position
  • Respondents’ capability and related experiences
    Preferred Collaboration Types
    Area of Interest